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T
he World Health Organization (WHO) considers
symptomatic sickle cell disease (SCD) the most deadly
genetic disease worldwide.1 Recently, the European
Hematology Association (EHA) reported that due to
migration, an increasing number of patients suffering from SCD
are living in almost every European country.2 Often combined
with blood transfusions, approved drugs are currently used to
reduce the incidence and severity of pain crises, hemolysis and
vaso-occlusive events (VOC). The main biological effect of the
standard-of-care treatment hydroxyurea is induction of fetal
hemoglobin (HbF) synthesis.3 Several new compounds with
different modes of action have been evaluated and licensed
recently including L-Glutamine, that decreases red blood cell
(RBC) oxidative injury4; Voxelotor, that elevates the oxygen
affinity to Hb, thus stabilizing the RBC in the oxygenated state,
thereby preventing HbS fiber formation5 and Crizanlizumab, an
anti-P-selectin antibody targeting adhesion of sickled RBCs to
endothelium and activation of platelets in VOCs.6
Earlier we reported that intracellular Ca2+ concentration in
human RBCs depends on the abundance and activity of N-methyl
D-aspartate receptors (NMDARs) that are present on the RBC’s
membrane.7 These non-selective cation channels are activated
when stimulated upon exposure to glutamate (homocysteine,
homocysteic acid) and glycine as well as by mechanical stimuli in
a variety of cell types including RBCs. Their activation results in a
transient excess of cellular Ca2+ uptake.7,8 NMDARs are
essential for cytoprotection and during maturation, of erythroid
precursors the number or receptors drops from hundreds of
thousands in a single proerythroblast to as little as 30 in young
healthy RBCs.9,10 Inhibition of NMDARs using the channel
inhibitor memantine (an approved anti-Alzheimer drug) resulted
in an acute decrease in intracellular free Ca2+ levels in RBCs of
healthy volunteers and SCD patients.7,9 Cells of SCD patients
responded to NMDAR inhibition with rehydration, sickling
reduction upon deoxygenation and with amelioration of
oxidative stress. Based on these ex vivo findings, we hypothesized
that NMDARs in the RBCs of SCD patients are a potential target
for pharmacological intervention. Memantine represents a
second generation NMDAR inhibitors combining safety and
low price and is used to treat dementia, autism and other
psychiatric conditions in adults, adolescent and children.11,12
In this proof-of-principle clinical phase 2 study termed
MemSID, 6 SCD patients (Fig. 1A) were enrolled and four
treated for up to 44 weeks with 5 to 20mg memantine
(clinicaltrials.gov: NCT02615847). The primary objective was
to test for safety and tolerability of the drug by SCD patients. The
impact of the therapy on quality of life (QoL) and major
hematological parameters were secondary objectives. The study
was divided into 5 periods (Fig. 1C): (i) screening (up to 4 weeks),
(ii) up-titration (4 weeks), (iii) treatment with 20mg memantine
(41–44 weeks), (iv) down-titration (3 weeks) and (v) follow-up
period (8 weeks). The planned total duration of the study was 56
to 59 weeks. For patient eligibility and study design see
Supplementary Data, http://links.lww.com/HS/A89. From the
nine intended patients, 2 could not be enrolled because of recent
transfusions and one withdrew before treated started (Fig. S1,
http://links.lww.com/HS/A89). All 6 patients had a HbSS
phenotype. For further information concerning demographics,
characteristics and co-medication with hydroxyurea (see
Fig. 1A). Two of 6 patients discontinued the study due to an
adverse event (AE; dizziness/vertigo, P6) and a severe AE (SAE;
psychosis, P5, see below and Fig. 1D). Memantine intake was
monitored by determining plasma levels (Fig. 1B). After up-
titration memantine levels were in a range of 30 to 90ng/ml
reflecting overall good compliance by the patients with three
exceptions that are mentioned below.
Figure 1D shows all AEs and SAEs of all 6 patients that started
the trial. Dizziness/vertigo and tachycardia were judged as AEs
possibly related to memantine, whereas dizziness/vertigo was
found to be the most common symptom in 4 out of 6 patients
(Fig. 1D, top). Accordingly, memantine dose was adjusted in 2
patients. One adjustment (P2 with grade III symptoms of
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dizziness/vertigo) was transient, having no further consequence
on the patient’s participation in the trial, while P6 (grade II
dizziness/vertigo) withdrew from the study. Of note, P6
retrospectively reported suffering from dizziness even before
the trial. The only observed SAE possibly related to memantine
was an acute psychosis that occurred in P5 and consequently,
memantine therapy was stopped immediately. Post-study analy-
sis of plasma memantine revealed that this symptom was timely
associated with very high plasma memantine levels reaching
values of 155 and 137ng/ml at week 5 and 9, respectively
(Fig. 1B, marked a), before withdrawing from the trial at week
11. This patient recovered completely without rebound effects.
We observed 2 additional elevations in plasma memantine levels
that did not lead to psychological changes. P3 increased drug
intake on his own during a pain crisis (Fig. 1B, marked b) and P4
reached similar high memantine plasma levels by accidentally
taking double doses at the beginning of the study (Fig. 1B,
marked c).
More AEs and SAEs were recorded but rated as not likely
related to treatment (Fig. 1D, bottom). Of these AEs some were
disease-related like transient pain, pain crises for over 4hours,
as well as urine analysis abnormalities and also infectious
complications. More non memantine-related SAEs were
patellar instability (with planned surgery) and disease-related
priapism in P1 as well as severe pain crises, pneumonia and
gastroenteritis in P4. Again, only one SAE (psychosis due to
suspected overdose) was likely related to memantine. Two
transfusion episodes were required during the study, one in
the case of patient P1 before planned surgery and the second
(2 units) in the case of P4 during pain crisis (1 unit). Knee
surgery in P1 was associated with interruption of blood supply
in the extremity, but the following hypoxemia did not lead to
pain crises.
Patients’ QoL was continuously scored throughout the trial
and the total score is summarized for each individual patient in
Figure S2, http://links.lww.com/HS/A89. Pain crisis and infec-
tions were found to be the most important factors that influenced
the scoring of the QoL. Three out of 4 patients showed a tendency
of improvement in total QoL score: patient P1 and P2 (the latter
upon reaching the full memantine dose) reported steady
Figure 1. Study design, information on the patients and plasmamemantine pharmacokinetics. A. Demographics of the SCD patients and characteristics
at enrolment. Sex, age, weight and family origin as well as the corresponding percentage of HbS andHbFmeasured during the screening period of patients P1-6 are
shown. All patients had the HbSS phenotype.
∗
number of previous transfusions that applied 9 to 12 months before enrolment. B. Plasma memantine
pharmacokinetics during the study periods. The analysis of the memantine concentration in the plasma of the patients revealed a good compliance during the trial
with the following exceptions: overdosing by the patient P5 (a) led to psychosis (SAE) and the trial was terminated. Overdosing by P3 (b) and P4 (c) caused reversible
increase in plasma memantine levels without discontinuation. Note that the memantine levels found in P6 who stopped the trail at week 5 was within the normal
range (not shown). C. Schematic representation of the trial periods. The study was divided into five periods as described in the Supplementary Data. D. Adverse
Effects (AE) and Severe Adverse Effects (SAE). The upper part of the table shows the AE and SAE that were attributed to memantine intake, while the lower part
reflects the AE and SAE that were considered as not likely related to memantine.
∗
Dizziness/vertigo led to a transient dose reduction (10mg per day for 10 days) that
was increased again to 20mg after cessation of this symptom.
∗∗
A pain crisis was defined as ongoing pain lasting for longer than 4hours (shorter pain periods are
defined as “transient pain”) and requiring the application of opiates or treatment at the out patients clinic or emergency department for less than 12hours.
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improvement during the trail. P3 started with a good QoL score
and suffered from pain crises at week 33 (upon which he
increased his memantine dose). Finally, P4 suffered from
repetitive gastrointestinal infections and pneumonia that trig-
gered hospitalizations (e.g., SAEs) after intercontinental flights
(week 20 and 25).
RBC count remained stable during all phases (Fig. 2, Table S2,
http://links.lww.com/HS/A89). Regression analysis (considering
blood transfusion and infection as control variables) showed no
significant changes (Table S1, http://links.lww.com/HS/A89). Hb
concentrations were more variable and showed a minor
reduction between screening and follow-up phase with 5.85
g/l (95%-CI: 11.5, 0.202g/l; p value: 0.043). In P1
reticulocyte number decreased, while in P2 and P4 it remained
stable, and in P3 it decreased when entering the follow-up phase
(Fig. 2). LDH activity decreased during the treatment period but
the overall level still remained elevated. Only P1 showed a major
reduction of bilirubin.
Plasma ferritin levels of patients P1, P2, and P3 were within the
normal range, for example, 62–131mg/l (Fig. 2, Table S2, http://
links.lww.com/HS/A89), whereas patient P4 started already with
elevated iron storage and plasma ferritin level >1500 mcg/l (not
shown inFig. 2 because out of scale but reported inTable S2, http://
links.lww.com/HS/A89). Patients P1, P2, and P3 responded
to memantine treatment with a decrease in plasma ferritin
(from regression analysis: screening phase 98.9mg/l to a fraction
of 42% (95%-CI: 29%–61%; p value < 0.001) of screening
phase estimate) (Table S1, http://links.lww.com/HS/A89: P1, P2,
and P3).
In agreement with ex vivo findings on rehydration of RBC
upon memantine treatment9 we observed an increase in
hypochrome and a decrease in hyperchrome RBC abundance
in all four patients (Fig. 2). P1 showed an increase of hypochrome
RBC from 7.5% to 29.7% (95%-CI: 29.0, 30.3%) and P2, P3
and P4 from 9.6, 4.6 and 2.0% to 24.3% (95%-CI: 20.1,
28.5%), 6.6% (95%-CI: 2.8, 10.4%) and 7.8% (95%-CI: 6.5,
9.1%), respectively (Fig. 2 and Table S2, http://links.lww.com/
HS/A89). Dehydration of RBCs of SCD patients facilitates
formation of HbS fibers that damage the cell membrane and
compromise deformability promoting hemolysis and VOCs.
Earlier, application of the Gardos channel blocker Senicapoc that
interferes with RBC’s water balance by retention of intracellular
K+was not found to reduce pain and VOCs.13Memantine, acting
upstream from the inhibition of Ca2+-dependent Gardos
channels, might have the potential to reduce VOCs.
In conclusion, our study on memantine in SCD patients
demonstrated comparable safety profile as described before for
memantine in Alzheimer‘s disease.11 All side effects were
transient and manageable and we observed a tendency to
improve QoL. More in depth analysis of memantine’s impact on
RBC characteristics is published elsewhere.14 Our study is not
powered to make any final conclusions on efficacy but the
obtained results on four patients that completed the study for one
year served as a precedent to conduct a larger trial including
young adults and adolescents that is now ongoing. Assuming that
memantine reduces SCD symptoms, this drug – in combination
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Figure 2. The impact of memantine on some RBC-related parameters. Means and 95%-CIs of RBC count, Hb, reticulocyte count, lactate dehydrogenase
(LDH) activity, ferritin and total bilirubin in plasma as well as percentage of hypochromic and hyperchromic RBC isolated from patients 1 to 4 before enrolment and
during the trial are shown. Note that the ferritin values for P4 reach levels around 1500mg/l and thus are not shown here but appear in Table S2, http://links.lww.






meaning p < 0.1, p<0.05, p<0.01, p<0.001, respectively;





The present work has been partially supported by the following
foundations: Baugarten Zürich Genossenschaft und Stiftung, the
Ernst Goehner Stiftung, the René und Susanna Braginsky
Stiftung, the Stiftung Symphasis and the Botnar Foundation.
We are also grateful to the Foundation for Clinical Research
Hematology for supporting the clinical trail at the Division of
Hematology, University Hospital Zurich.
Disclosures
The authors have no conflicts of interest to disclose. The
University of Zurich holds the patent to use memantine against
sickle cell disease.
References
1. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of sickle
haemoglobin in neonates: a contemporary geostatistical model-based
map and population estimates. Lancet. 2013;381:142–151.
2. Iolascon A, De Franceschi L, Muckenthaler M, et al. EHA research
roadmap on hemoglobinopathies and thalassemia: an update. Hema-
Sphere. 2019;3:e208.
3. McGann PT, Ware RE. Hydroxyurea therapy for sickle cell anemia.
Expert Opin Drug Saf. 2015;14:1749–1758.
4. Niihara Y, Miller ST, Kanter J, et al. A phase 3 trial of l-glutamine in sickle
cell disease. N Engl J Med. 2018;379:226–235.
5. Vichinsky E, Hoppe CC, Ataga KI, et al. A phase 3 randomized
trial of voxelotor in sickle cell disease.N Engl J Med. 2019;381:509–519.
6. Ataga KI, Kutlar A, Kanter J, et al. Crizanlizumab for the
prevetntion of pain crises in sickle cell disease. N Engl J Med.
2017;376:429–439.
7. Makhro A, Hanggi P, Goede JS, et al. N-methyl D-aspartate (NMDA)
receptors in human erythroid precursor cells and in circulating red
blood cells contribute to the intracellular calcium regulation. Am J
Physiol Cell Physiol. 2013;305:C1123–C1138.
8. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact
on receptor properties, synaptic plasticity and disease. Nat Rev
Neurosci. 2013;14:383–400.
9. Hanggi P, Makhro A, Gassmann M, et al. Red blood cells of sickle cell
disease patients exhibit abnormally high abundance of N-methyl D-
aspartate receptors mediating excessive calcium uptake.Br J Haematol.
2014;167:252–264.
10. Hanggi P, Telezhkin V, Kemp PJ, et al. Functional plasticity of the N-
methyl-d-aspartate receptor in differentiating human erythroid precur-
sor cells. Am J Physiol Cell Physiol. 2015;308:C993–C1007.
11. Kavirajan H. Memantine: a comprehensive review of safety and
efficacy. Expert Opin Drug Saf. 2009;8:89–109.
12. Rossignol DA, Frye RE. The use of medications approved for
Alzheimer’s disease in autism spectrum disorder: a systematic review.
Front Pediatr. 2014;2:87.
13. Ataga KI, Reid M, Ballas SK, et al. Improvements in haemolysis and
indicatorsof erythrocytesurvivaldonotcorrelatewithacutevaso-occlusive
crises in patients with sickle cell disease: a phase III randomized, placebo-
controlled, double-blind study of the Gardos channel blocker senicapoc
(ICA-17043). Br J Haematol. 2011;153:92–104.
14. Makhro A, Hegemann I, Seiler E., et al. A pilot clinical phase II
trial MemSID: Acute and durable changes of red blood cells of sickle cell
disease patients on memantine treatment. eJHaem. 2020;190:1–12.
Letter Letter
4
